June 29, 2020 -- ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further testing and possible inclusion in the company's PolyTope monoclonal antibody therapy against COVID-19.
The selected lead antibodies are the result of functional screening of over 300 antibodies analyzed from human and llama cells utilizing proprietary phage display technology. These antibodies support the company's goal of generating a multitarget therapy that retains efficacy, even as SARS-CoV-2 continues to evolve.
The company is preparing to test the lead antibodies against additional mutated strains of the virus with preclinical studies slotted to begin this summer.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
